on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics announces its 2026 Combined General Meeting
GenSight Biologics, a biopharmaceutical company specializing in gene therapies for neurodegenerative diseases, will hold its Combined General Meeting on May 19, 2026. This meeting will take place at the company's headquarters in Paris, as well as via live online broadcast.
The agenda and draft resolutions were published on April 13, 2026, in the BALO (Bulletin des Annonces Légales Obligatoires). A formal notice of meeting is scheduled for May 4, 2026. Preparatory documents are available on the GenSight Biologics website and at the company headquarters.
Shareholders may request, up to five days before the meeting, the documents and information required by the articles of the Commercial Code. These requests should preferably be sent by email, providing proof of shareholder status.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news